CME Group: The Price Stands Still, But The Growth Engines Accelerate

CME Group remains a Buy, driven by robust volumes, an expanding fixed-income ecosystem, and product innovation, despite a full valuation. CME's Q2 2026 saw record revenues, strong margins near 70%, and notable growth in international and retail trading volumes. Key catalysts include Treasury Link integration, 24/7 trading, Compute futures, and regulatory tailwinds in clearing requirements. Competition from perpetual futures and a premium valuation at 21x forward earnings temper near-term upside, but long-term growth and capital returns support the rating.

I last wrote about CME Group (CME) in April 2025 and gave the stock a Buy rating at around $271. Now CME is trading around $275, and the total return amounts to only 5.5%. My previous Buy